Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Recently published papers: Pseudomonas, brain and bowel injury and novel cardiac therapies. | Available online http content 12 5 184 Commentary Recently published papers Pseudomonas brain and bowel injury and novel cardiac therapies Uma M Bandarupalli and Gareth Williams University Hospitals of Leicester NHS Trust Infirmary Square Leicester LE1 5WW UK Corresponding author Gareth Williams Published 14 October 2008 This article is online at http content 12 5 184 2008 BioMed Central Ltd Critical Care 2008 12 184 doi cc7019 Abstract Ventilator-associated pneumonia is a familiar foe in intensive care units but those associated with Pseudomonas aeruginosa have a particularly adverse impact on outcome. Correct antibiotic therapy and a novel endotracheal tube may reduce this burden. Does activated protein C improve outcome from acute lung injury and what is the role played by hyperventilation therapy in traumatic brain injury Recent research has attempted to answer these questions. Further novel approaches have been evaluated in the management of ischaemic heart disease and more light has been shed on acute bowel injury. Ventilator-associated pneumonia Ventilator-associated pneumonia VAP is strongly associated with adverse outcomes in mechanically ventilated patients in the intensive care unit ICU . Its incidence is about 8 to 20 1 and mortality ranges between 20 and 50 2 . Consequently VAP has considerable impact on morbidity length of stay and cost of ICU care 3 4 . Kollef and coworkers 5 conducted a retrospective cohort study involving 76 patients in an urban tertiary hospital who were recruited over 5 years. The objective was to identify predictors of 30-day mortality and hospital costs in patients with VAP attributed to potentially antibiotic-resistant Gramnegative bacteria Pseudomonas aeruginosa Acinetobacter spp. and Stenotrophomonas maltophilia . Overall mortality was 25 . Patients receiving their first dose of appropriate antibiotic therapy within 24 hours of bronchoalveolar lavage BAL sampling
